Anika Therapeutics Inc (ANIK) Stock Price

ANIKStock

$19.98+119.80%52W

Market Cap$267.39M

P/E—

PEG Ratio2.13

Div yield—

Beta0.23

ANIK Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)20.68%

Price vs S&P 500 (4W)-2.15%

PEG Ratio2.13

VGM Score49.87

P/CF (Annual)23.90x

Book Value / Share (Quarterly)$10.26

P/TBV (Annual)0.98x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-10.28%

Cash Flow / Share (Quarterly)$0.04

Price vs S&P 500 (YTD)95.98%

Gross Margin (TTM)62.16%

Net Profit Margin (TTM)-3.14%

EPS (TTM)$-0.27

10-Day Avg Trading Volume0.11M

EPS Excl Extra (TTM)$-0.27

Revenue Growth (5Y)-2.87%

EPS (Annual)$-0.76

ROI (Annual)-7.58%

Gross Margin (Annual)56.56%

Net Profit Margin (5Y Avg)-22.61%

Cash / Share (Quarterly)$2.87

Revenue Growth QoQ (YoY)15.56%

ROA (Last FY)-5.72%

Revenue Growth TTM (YoY)-2.50%

EBITD / Share (TTM)$0.04

ROE (5Y Avg)-17.39%

Operating Margin (TTM)-4.24%

Cash Flow / Share (Annual)$0.31

P/B Ratio1.95x

P/B Ratio (Quarterly)1.42x

Net Income / Employee (Annual)$-46,300

EV / Revenue (TTM)1.90x

Net Interest Coverage (TTM)13.00x

ROA (TTM)-2.04%

EV / EBITDA (TTM)457.96x

EPS Incl Extra (Annual)$-0.76

Current Ratio (Annual)4.72x

Quick Ratio (Quarterly)3.05x

3-Month Avg Trading Volume0.10M

52-Week Price Return119.80%

EV / Free Cash Flow (Annual)52.49x

Revenue / Employee (TTM)$513,400

Tangible BV / Share (Quarterly)$10.13

P/S Ratio (Annual)2.37x

Asset Turnover (Annual)0.59x

52-Week High$22.88

Operating Margin (5Y Avg)-4.84%

EPS Excl Extra (Annual)$-0.76

CapEx CAGR (5Y)33.17%

Tangible BV CAGR (5Y)-4.78%

26-Week Price Return30.59%

Quick Ratio (Annual)3.71x

13-Week Price Return31.02%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.48x

Enterprise Value$228.98M

Revenue / Share Growth (5Y)-3.06%

Asset Turnover (TTM)0.65x

Book Value / Share Growth (5Y)-11.52%

Revenue / Employee (Annual)$480,100

Inventory Turnover (Annual)2.30x

Pretax Margin (Annual)-8.25%

Cash / Share (Annual)$4.14

3-Month Return Std Dev48.64%

Gross Margin (5Y Avg)57.20%

Net Income / Employee (TTM)$-16,100

EBITDA CAGR (5Y)-46.37%

EBITDA Interim CAGR (5Y)-18.86%

ROE (Last FY)-7.58%

Net Interest Coverage (Annual)-7.33x

EPS Basic Excl Extra (Annual)$-0.76

P/FCF (TTM)29.80x

Receivables Turnover (TTM)4.55x

EV / Free Cash Flow (TTM)407.44x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.27

Receivables Turnover (Annual)4.77x

ROI (TTM)-2.70%

P/S Ratio (TTM)2.22x

Pretax Margin (5Y Avg)-3.80%

Revenue / Share (Annual)$7.87

Tangible BV / Share (Annual)$10.21

Forward P/E93.05x

Free OCF CAGR (5Y)-17.54%

Price vs S&P 500 (52W)104.27%

Year-to-Date Return107.91%

5-Day Price Return-2.39%

EPS Normalized (Annual)$-0.76

ROA (5Y Avg)-13.43%

Net Profit Margin (Annual)-9.64%

Month-to-Date Return1.63%

Cash Flow / Share (TTM)$-0.69

EBITD / Share (Annual)$-0.40

Operating Margin (Annual)-9.80%

LT Debt / Equity (Annual)0.07x

P/CF (TTM)44.74x

ROI (5Y Avg)-17.39%

LT Debt / Equity (Quarterly)0.09x

EPS Basic Excl Extra (TTM)$-0.27

P/TBV (Quarterly)1.44x

P/B Ratio (Annual)0.97x

Inventory Turnover (TTM)2.01x

Pretax Margin (TTM)-2.41%

Book Value / Share (Annual)$10.33

Price vs S&P 500 (13W)28.33%

Beta0.23x

P/FCF (Annual)61.30x

Revenue / Share (TTM)$8.80

ROE (TTM)-2.70%

52-Week Low$8.67

vGradeC

gGradeD

mGradeA

vgmGradeC

ANIK Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 29, 2026	$0.03	$0.42	+1300.00%(+$0.39)
Q1 2026	Apr 29, 2026	$0.00	$0.27	+0.00%(+$0.27)
Q4 2025	Feb 26, 2026	$0.02	$0.31	+1450.00%(+$0.29)
Q3 2025	Nov 5, 2025	$0.02	$0.04	+100.00%(+$0.02)
Q2 2025	Jul 30, 2025	-$0.13	-$0.13	+0.00%(+$0.00)

ANIK Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.25

Industry Peers — Surgical & Medical Instruments(142)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth (5Y)	Gross Margin (TTM)	Operating Margin (TTM)	Price
ANIKAnika Therapeutics Inc	C	D	A	2.2x	-2.9%	62.2%	-4.2%	$19.98
SYKStryker Corporation	C	B	C	4.4x	11.8%	65.3%	21.3%	$294.66
MMM3M Company	C	D	B	3.4x	-5.0%	39.4%	18.4%	$164.75
BSXBoston Scientific Corp.	C	B	C	3.1x	15.2%	69.5%	19.8%	$44.39
BDXBecton, Dickinson and Co.	B	D	A	2.5x	6.3%	46.7%	9.6%	$191.75
MDLNMedline Inc. Class A common stock	C	D	C	1.6x	—	26.2%	6.0%	$35.96
RMDResMed Inc.	C	C	B	5.9x	12.1%	61.1%	33.4%	$238.97
DXCMDexCom, Inc.	C	B	B	6.5x	19.3%	64.3%	22.9%	$86.04
WSTWest Pharmaceutical Services, Inc.	D	C	A	8.5x	7.4%	36.8%	20.4%	$384.02
SOLVSolventum Corporation	C	C	B	1.8x	—	54.8%	23.9%	$85.81
BAXBaxter International Inc.	B	D	B	1.1x	-0.8%	30.7%	-2.3%	$25.28
PENPenumbra, Inc.	F	C	B	8.4x	20.2%	67.8%	12.4%	$320.86
GMEDGLOBUS MEDICAL INC	B	B	B	3.3x	30.1%	68.5%	20.6%	$76.71
PODDInsulet Corporation	C	A	C	3.2x	24.5%	71.1%	16.9%	$141.10
GKOSGlaukos Corporation	F	A	B	15.9x	17.7%	79.1%	-31.6%	$164.84
TFXTeleflex Incorporated	B	F	B	2.1x	-4.7%	53.8%	-11.7%	$130.43
HAEHaemonetics Corporation	C	C	A	4.0x	8.9%	59.1%	11.9%	$118.28
MMSIMerit Medical Systems Inc	C	B	B	3.4x	9.5%	49.5%	12.8%	$89.20
STVNStevanato Group S.p.A.	D	C	C	3.7x	12.4%	29.9%	16.4%	$18.90
MMEDMiniMed Group, Inc. Common Stock	—	—	B	—	—	—	—	$17.49
HTFLHeartflow, Inc. Common Stock	F	A	A	19.8x	—	80.1%	-40.8%	$48.29
ICUIICU Medical Inc	C	D	B	1.9x	11.9%	39.1%	3.5%	$162.99
IRTCiRhythm Holdings, Inc. Common Stock	D	B	C	4.3x	23.0%	71.5%	-3.0%	$108.66
PLSEPulse Biosciences, Inc Common Stock (DE)	F	—	A	2725.9x	—	0.3%	-7007.8%	$44.43
ATRCAtriCure, Inc.	D	B	A	5.0x	20.9%	76.3%	2.3%	$56.07
UFPTUFP Technologies Inc	C	B	A	3.6x	27.4%	28.5%	15.3%	$291.67
INSPInspire Medical Systems, Inc.	B	B	B	2.2x	51.2%	86.1%	6.0%	$68.79
LMATLeMaitre Vascular, Inc.	C	B	C	7.0x	14.0%	72.9%	29.5%	$80.82
NVCRNovoCure Limited Ordinary Shares	D	C	C	2.3x	5.8%	76.1%	-22.1%	$14.07
KMTSKestra Medical Technologies, Ltd. Common Stock	F	A	B	15.2x	—	53.9%	-140.4%	$27.24
ATECAlphatec Holdings, Inc.	D	B	C	2.0x	39.5%	70.8%	-7.5%	$10.46
DRTSAlpha Tau Medical Ltd. Ordinary Shares	—	—	B	—	—	—	—	$12.29
TNDMTandem Diabetes Care, Inc.	D	C	C	1.1x	15.3%	56.0%	-4.4%	$16.24
IRMDiRadimed Corporation	D	B	B	13.1x	21.4%	75.9%	31.9%	$88.27
AORTArtivion, Inc.	C	C	C	2.3x	11.8%	64.4%	2.9%	$21.78
IARTIntegra LifeSciences Holdings	B	F	C	0.6x	3.6%	57.2%	4.0%	$13.21
PRCTPROCEPT BioRobotics Corporation Common Stock	C	A	D	3.0x	109.0%	64.2%	-33.9%	$17.57
BVSBioventus Inc. Class A Common Stock	B	C	A	1.9x	12.1%	68.7%	10.0%	$13.30
BBNXBeta Bionics, Inc. Common Stock	D	A	C	7.4x	—	58.3%	-69.8%	$16.35
SIBNSI-BONE, Inc. Common Stock	D	B	B	4.1x	22.3%	79.5%	-8.3%	$19.68
SGPSpyGlass Pharma, Inc. Common Stock	—	—	B	—	—	—	—	$24.00
MDXGMiMedx Group, Inc	C	D	C	1.8x	11.0%	78.8%	2.5%	$4.43
KIDSOrthoPediatrics Corp. Common Stock	C	B	B	2.3x	27.2%	73.7%	-11.9%	$21.95
TCMDTactile Systems Technology, Inc.	B	B	B	1.5x	12.0%	51.9%	10.0%	$22.52
SSIISS Innovations International Inc. Common Stock	F	A	D	9.7x	—	47.6%	-16.2%	$2.53
DCTHDelcath Systems Inc	D	C	B	5.1x	120.1%	87.0%	-1.9%	$14.08
ANGOAngioDynamics, Inc.	C	D	C	1.5x	1.9%	55.6%	-11.2%	$11.24
BWAYBrainsway Ltd. American Depositary Shares	D	B	B	9.5x	12.2%	74.9%	5.8%	$11.44
SGHTSight Sciences, Inc. Common Stock	D	B	A	5.5x	22.9%	88.4%	-33.4%	$8.28
CERSCerus Corp	D	C	C	1.8x	15.4%	57.2%	-0.7%	$2.18
NPCENeuropace, Inc. Common Stock	D	C	C	4.3x	19.4%	79.6%	-15.3%	$12.24

About Anika Therapeutics Inc

Anika Therapeutics develops osteoarthritis pain management solutions using proprietary hyaluronic acid technology. The company's principal products—Orthovisc, Monovisc, and Cingal—are office-administered viscosupplement products marketed exclusively in the U.S. by Johnson & Johnson MedTech. Primary revenue is derived from the U.S. market, with additional contributions from OEM licensing and international operations.

ANIK Next Earnings Report

Report dateNov 4, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate$0.42

Revenue estimate$29.44M

Also reporting on Nov 4, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

ANIK Insider Transactions

BuyAug 4, 2026
FISCHETTI GARY P.
Director
Shares: 2,000Value: $41,060

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

FOSLFossil Group, Inc.Watches & Clocks
PREPrenetics Global Limited Class A Ordinary ShareLab Analytical Instruments
CVCapsoVision, Inc. Common StockElectromedical Equipment
SMTISanara MedTech Inc. Common StockOrthopedic & Prosthetic Devices
OPTXSyntec Optics Holdings, Inc. Class A Common StockOptical Instruments & Lenses
NAUTNautilus Biotechnolgy, Inc. Common StockLab Analytical Instruments
EYPTEyePoint, Inc. Common StockLab Analytical Instruments
QSIQuantum-Si Incorporated Class A Common StockMeasuring & Controlling Devices

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$8.67

High$22.88